logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10383873 B1

PDFFull Text
Date of Patent:
Aug. 20, 2019

Filed:

Apr. 02, 2015

Method and kits for identifying of cdk9 inhibitors for the treatment of cancer

Applicants:

Memorial Sloan-kettering Cancer Center, New York City, NY (US);

St. Jude Children's Research Hospital, Memphis, TN (US);

Inventors:

Scott William Lowe, New York City, NY (US);

Charles J. Sherr, Memphis, TN (US);

Chun-Hao Huang, New York City, NY (US);

Amaia Lujambio, New York City, NY (US);

Assignees:

MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US);

ST. JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, TN (US);

Attorney:

Hunton Andrews Kurth LLP

Primary Examiner:

Celine X Qian

Int. Cl.
CPC ...
C12Q 1/68 (2018.01); A61K 31/519 (2006.01); A61K 31/445 (2006.01); G01N 33/574 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 31/40 (2006.01); A61K 31/404 (2006.01); A61K 31/44 (2006.01); A61K 31/4545 (2006.01); A61K 31/4745 (2006.01); A61K 31/655 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/40 (2013.01); A61K 31/404 (2013.01); A61K 31/44 (2013.01); A61K 31/445 (2013.01); A61K 31/4545 (2013.01); A61K 31/4745 (2013.01); A61K 31/655 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 45/06 (2013.01); C12N 15/1137 (2013.01); C12Q 1/6886 (2013.01); C12Y 207/11022 (2013.01); C12Y 207/11023 (2013.01); G01N 33/57423 (2013.01); G01N 33/57426 (2013.01); G01N 33/57438 (2013.01); C12N 2310/531 (2013.01); C12N 2320/10 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/91205 (2013.01); G01N 2800/52 (2013.01);
Abstract

A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.

Find Patent Forward Citations

Loading…